Peel Therapeutics a US-based clinical-stage biotech company developing medicines for cancer and inflammatory diseases, announced on Wednesday that it has started a first-in-human clinical study of PEEL-224 in patients with advanced solid tumours.
This move is subsequent to the recent acceptance of the company's Investigational New Drug (IND) Application by the United States Food and Drug Administration (FDA).
The product was produced from a medicine that originates from the leaves and stem of an ancient tree used for thousands of years in traditional Chinese medicine.
The firm is assessing the product in a Phase one dose escalation, repeat-dose, multi-centre, open-label study in patients with advanced solid tumours. The trial is to assess PEEL-224's safety, tolerability, pharmacokinetics and preliminary antitumor activity.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial